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Abstract 
 
Objective: Large-scale prospective studies do not support an association between neuroticism 
and extroversion with cancer incidence. However, research on other personality constructs is 
inconclusive. This longitudinal study examined the associations between four personality 
measures, Type 1 "suppressed emotional expression," Type 5 "rational/anti-emotional," 
hostility and Type A with cancer incidence. 
Methods: Personality measures were available for 13,768 members in the GAZEL cohort 
study (baseline assessment in 1993). Follow-up for diagnoses of primary cancers was 
obtained from January 1, 1994 to December 31, 2009. Associations between personality and 
cancer incidence were evaluated using Cox proportional hazards analyses and adjusted for 
potential confounders. 
Results: During a median follow-up of 16.0 years [range: 9 days-16 years], 1,139 participants 
received at least one diagnosis of primary cancer. The mean duration between baseline and 
cancer diagnosis was 9.3 years. Type 1 personality was associated with a decreased risk of 
breast cancer [hazard ratio (HR) per standard deviation: 0.81, 95% confidence interval (CI) = 
0.68-0.97, p=.02]. Type 5 personality was not associated with prostate, breast, colorectal or 
smoking-related cancers, but was associated with other cancers (HR per standard deviation: 
1.17, 95% CI = 1.04-1.31, p=.01). Hostility was associated with an increased risk of smoking-
related cancers, which was explained by smoking habits, and Type A was not associated with 
any of the cancer end-points. 
Conclusions: Several personality measures were prospectively associated with the incidence 
of selected cancers. These links may warrant further epidemiological studies and 
investigations about potential biobehavioral mechanisms. 
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Introduction 
 
Personality has long been hypothesized to predispose individuals to cancer initiation or 
progression. The early observation by Kissen and Eysenck (1) that patients with lung cancer 
may show high levels of extroversion and low levels of neuroticism led to posit a “cancer-
prone” personality. However, well-designed large-scale prospective studies have convincingly 
dismissed this initial hypothesis (2-6). According to the International Agency for Research on 
Cancer (7), excluding a risk factor as carcinogenic warrants 1) several methodologically 
sound studies that 2) are mutually consistent in not showing a positive association. Whereas 
these two criteria may be considered as fulfilled as regards extroversion and neuroticism (8), 
most of studies that addressed other personality constructs had serious methodological 
limitations: a retrospective or cross-sectional design, a focus on cancer mortality rather than 
cancer incidence, a lack of comprehensive adjustment on confounding variables, a short 
follow-up period or a relatively small sample size, resulting in insufficient statistical power to 
analyze specific cancer sites. Overall, these studies have mostly produced negative results or 
mixed results at best (9-12). The present study took advantage of the large-scale prospective 
French GAZEL cohort (13) to examine the association between cancer incidence and four 
measures of personality. 
Type 1 personality, characterized by suppressed emotional expression in the context of 
interpersonal relationships, and Type 5 personality, characterized by rational/anti-emotional 
tendencies, were proposed by Grossarth-Maticek and Eysenck (14) to account for the early 
observation of a negative association between neuroticism and cancer (1). These two 
personality types were claimed to be associated with poor stress coping strategies, resulting in 
high levels of cortisol and related immune deficiencies (14). Owing to serious methodological 
and ethical issues, it was suggested that the early reports by these authors, supporting a strong 
link with cancer, should be withdrawn from the literature (8, 15, 16), making these personality 
constructs unfashionable for psychosomatic research. As a consequence, the hypothesis of 
their association with cancer incidence remains to be properly tested, whereas these early, 
questionable results still influence the results of recent impactful meta-analyses (16). The 
primary aim of the present study was to challenge these results focusing on cancer incidence 
rather than mortality. Type 5 personality was found to predict poor survival among lung 
cancer patients (17) but some prospective studies failed to find significant associations 
between other measures of rational/anti-emotional tendencies and cancer incidence (18-21) or 
mortality (22). However, none specifically examined Type 5 personality and cancer incidence 
and most well-designed studies considered only breast cancer (19, 21) or were underpowered 
to properly analyze specific cancer sites (18, 20). Finally, there is evidence linking related 
constructs such as alexithymia with deficiencies in cell-mediated immunity (23), suggesting 
possible causal pathways between Type 5 and cancer onset. 
Here, we examined the associations between cancer incidence and Type 1 and Type 5 
personality measures in the GAZEL cohort study, considering several main sites of cancer 
separately. In addition, we report exploratory analyses regarding two other personality 
constructs more widely accepted in psychosomatic research: Type A behavior pattern and 
hostility. Statistical analyses specifically addressed the potential role of several health 
behaviors, such as smoking habits, in mediating any association between personality and the 
risk of cancer (11, 12). 
Material and Methods 
 
Participants 
 
Details of the GAZEL cohort study are available elsewhere (13). The target population 
consisted of 44,992 employees of the French national gas and electricity company “Electricité 
de France-Gaz de France” (EDF-GDF): 31,411 men aged 40-50 and 13,511 women aged 35-
50. The study protocol was approved by the French authority for data confidentiality 
(“Commission Nationale Informatique et Liberté”) and by the Ethics Evaluation Committee 
of the “Institut National de la Santé et de la Recherche Médicale” (INSERM) (IRB0000388, 
FWA00005831). In 1989, 20,625 employees (45.8%) (15,011 men and 5,614 women) gave 
written informed consent to participate in the GAZEL cohort study. Since then, participants 
were followed by means of an annual mailed questionnaire, as well as through administrative 
databases. The 1993 questionnaire, which was mailed to the 20,488 alive cohort members, 
included the Personality-Stress Inventory (PSI), the Buss and Durkee Hostility Inventory 
(BDHI) and the Bortner Type A Rating Scale (BTARS). 
 
Personality measures 
 
The PSI is a 70-item questionnaire with „true-false‟ answers that aims to identify 6 
personality types, each claimed to be specifically associated with increased or decreased 
morbid risks (14). Five of the personality scales are measured by 10 items each (sum of the 
„true‟ responses), and one (Type 4) is measured by 20 items (sum of the „true‟ responses, 
divided by 2). Six personality scores ranging from 0 to 10 are thus calculated. A pilot study in 
1991 among a random sample of 408 male GAZEL cohort members examined the 3-month 
retest reliability of the French version of the PSI (24). The 6 subscales of the PSI assess the 
following constructs: Type 1 = dependence on withdrawing objects (i.e. either persons or 
situations), leading to suppressed emotional expression in the context of interpersonal 
relationships; Type 2 = dependence on disturbing objects, leading to hostile thoughts and 
feelings; Type 3 = dependence on objects that are both withdrawing and disturbing, leading to 
ambivalent behaviors oscillating between the positive and negative aspects of the objects; 
Type 4 = autonomy and self-regulation; Type 5 = rational/anti-emotional tendencies ; Type 6 
= antisocial tendencies. Here, we focused on Type 1 and Type 5 subscales for three main 
reasons: first, we aimed to limit multiple comparisons as much as possible; second, we 
nonetheless aimed to challenge previous results linking Type 1 and Type 5 with cancer; third, 
a principal component analysis suggested that Types 1, 2, 3 and, inversely, Type 4 may 
indeed relate to the same latent construct, whereas Types 5 and 6 may represent independent 
constructs (25). 
Type 1 personality (Cronbach‟s α = 0.61 in the GAZEL cohort, 3-month retest r 
coefficient = 0.65, p<.001), is close to the type C personality proposed by Temoshok (26). It 
is characterized by a tendency to suppress negative emotions, especially anger, and to be 
unassertive in order to seek harmony with others (e.g. “I often feel inhibited when it comes to 
openly showing negative feelings such as hatred, aggression, or anger”). Type 1 correlates 
positively with emotion-oriented coping strategies, neuroticism and alexithymia, and 
negatively with extraversion (27). 
Type 5 personality (Cronbach‟s α = 0.57 in the GAZEL cohort, 3-month retest r 
coefficient = 0.63, p<.001), once referred to as “rational/anti-emotional”, shares a tendency to 
suppress emotion with Type 1 personality but also features non-emotional and rational 
tendencies such as inhibited emotional reactions and lack of confidence in one's own feelings 
(e.g. “I can only express feelings when they have a rational basis”). Type 5 correlates 
positively with task-oriented coping strategies and alexithymia, and negatively with 
psychoticism. It does not correlate with neuroticism or extraversion (27).  
Hostility was assessed with the French version of Buss and Durkee Hostility Inventory 
(BDHI) (24, 28). The BDHI is composed of 75 items with „true-false‟ answers. It has eight 
subscales, seven of which are designed to measure different components of hostility: assault, 
verbal aggression, indirect hostility, irritability, negativism, resentment, and suspicion. The 
sum of these seven sub-scales leads to a „total hostility‟ score with a high 3-month test-retest 
reliability (r = 0.87, p<.001) (24). In order to limit multiple comparisons, we focused on the 
total hostility score (Cronbach‟s α = 0.88 in the GAZEL cohort). 
Although the 1991 pilot study (24) considered the Jenkins Activity Survey as index of 
Type A personality, the 1993 questionnaire included the Bortner Type A Rating Scale 
(BTARS) (29). It consists of 14 items each comprising two statements with a graded scale 
between the two statements (24-point scale in the original version, 6-point scale in the version 
adapted for the GAZEL cohort). Examples of statements include „never late‟ versus „casual 
about appointments‟. Importantly, the BTARS captures time urgency, job involvement, hard 
driving, need for achievement, ambition and competitiveness, but not hostility. The sum of 
the 14 items yields a global score ranging from 14 to 84 (Cronbach‟s α = 0.64 in the GAZEL 
cohort). This scale was translated and validated for the French population against the 
Friedman and Rosenman (30) structured interview for assessing Type A, agreement observed 
71.5% (31). 
 
Cancer cases 
 
All participants were followed-up for diagnoses of primary cancers from January 1, 
1994 to December 31, 2009. Diagnoses of primary cancer came from two sources. Diagnoses 
during the period of employment came from a registry kept by the medical departments at 
EDF-GDF and that has been validated for accuracy and completeness (32). Diagnoses after 
retirement came from the systematic validation of each self-reported primary cancer through a 
diagnosis validation survey that began in 2009. Each annual questionnaire asked participants 
to report whether or not they were hospitalized or diagnosed with several diseases; including 
cancer. All participants who self-reported a cancer at least once during the follow-up were 
contacted (if alive) to give consent for a detailed diagnostic investigation with their physician. 
In a first set of analyses, we considered as cases all participants with a validated 
diagnosis as well as participants who reported a diagnosis of primary cancer but who died 
from a cancer before the onset of the diagnosis validation survey. Living status and the date of 
death were obtained annually for all participants from EDF-GDF itself as it pays out 
retirement benefits. Causes of death were available from baseline (i.e. January 1, 1994) to 
December 31, 2009 and were coded by the French national cause-of-death registry (CépiDc, 
INSERM) using the ICD 9
th
 and 10
th
 Revision.
 
We planned to examine the four most frequent types of cancer in France, separately: 
prostate cancer in men, breast cancer in women, smoking-related cancers (i.e. cancer of the 
oral cavity and pharynx, esophagus, larynx, trachea, bronchi and lungs, and bladder) and 
colorectal cancer (33). A fifth category encompassing all other sites was also examined. Non-
melanoma skin cancers and in situ neoplasms were not considered as cancer cases. 
 
Covariates 
 
Age, sex, and occupation grade (blue-collar workers or clerks, first-line supervisors or 
sales representatives, management) were obtained from employer‟s human resources files at 
baseline. Alcohol consumption, smoking, fruits and vegetables consumption (<1, 1-2, >2 
times per week), height, weight, physical activity (at least one time per week, occasionally, 
none) and perceived health status were self-reported at baseline. Alcohol consumption, as 
drinks per week, was categorized as non-drinkers, occasional and moderate drinkers (1–27 for 
men, 1–20 for women) or heavy drinkers (≥28 for men, ≥21 for women). Smoking in the 
same period was categorized into 5 classes: never-smokers, ex-smokers of fewer than 20 
pack-years, current smokers of fewer than 20 pack-years, ex-smokers of more than 20 pack-
years and current smokers of more than 20 pack-years. Body mass index (BMI) was 
calculated by dividing weight in kilograms by height in meters squared and categorized as < 
18.5, 18.5–24.9, 25–29.9 or ≥30 kg/m2. Perceived health status was reported with an 8-point 
Likert scale ranging from 1 („very bad‟) to 8 („very good‟). 
 
Statistical analyses 
 
All statistical analyses were computed with PASW 18.0.0 software (SPSS Inc.). 
Personality scores had a normal distribution. Coefficients of correlation and ANOVAs were 
computed to examine the relation of personality scores with continuous and discrete 
covariates, respectively. The association of personality scores and covariates with cancer 
incidence was estimated with Hazard Ratios (HR) and 95% confidence intervals (CI) 
computed in Cox regressions. The follow-up ran from January 1, 1994 to the date of cancer 
diagnosis, death, refusal to receive further questionnaire, or December 31, 2009, whichever 
occurred first. For participants who reported a diagnosis of cancer after retirement, but who 
died from a cancer before the onset of the diagnosis validation survey, the estimated date of 
diagnosis was the date of the first self-report minus 180 days (i.e. the mean interval between 
two annual questionnaires). Discrete covariates were considered as nominal variables. Each 
personality score was considered as a continuous variable as we did not have a priori 
hypotheses to posit a more sophisticated relationship than a linear one. 
To test the hypothesis that some personality features might increase the risk of cancer 
through their influence on health behaviors (e.g. smoking habits), unadjusted analyses and 
two multivariate models were computed. Model 1 was adjusted for all covariates except for 
health behaviors, whereas model 2 was further adjusted for health behaviors (i.e. alcohol 
consumption, smoking, fruits and vegetables consumption and physical activity). Whenever a 
personality measure was significantly associated with cancer in model 1, the contribution of 
health behaviors to this association was appreciated by the percentage of change in the HR 
from model 1 to model 2, calculated with the following formula: 100 × (HR model 2 – HR model 
1) / (HR model 1 – 1). 
Model 2a included all the cancer cases for which we had a date of diagnosis (see 
above). In sensitivity analyses, we also considered two additional models. In model 2b, which 
aimed at optimizing the diagnosis sensitivity, all the participants who died from a cancer were 
considered as cases, including those who did not report a diagnosis of cancer during the 
follow-up. The estimated date of diagnosis was the date of death minus 886 days (i.e. the 
mean survival time among participants with an ascertained date of diagnosis and who 
subsequently died from a cancer). In model 2c, which aimed at optimizing the diagnosis 
specificity, only participants with a validated diagnosis of cancer were considered as cases, 
excluding participants who reported a cancer during the follow-up but died from a cancer 
before the diagnosis validation survey. 
Results 
 
All personality scores (i.e. Type 1, Type 5, hostility and Type A) were available for 
14,522 GAZEL cohort members (70.8%). Compared with non responders, responders were 
more likely to be male, older, to have a higher occupational grades, to eat fruits and 
vegetables more than twice a week and to have physical activity at least once a week, and 
were less likely to be heavy or non drinkers or current smokers and to have extreme BMI (all 
p<.05). 
Among the responders, 754 (5.2%) were excluded from this study: 18 died and one 
asked to receive no further questionnaire before the beginning of the follow-up (i.e. January 1, 
1994); 203 had previously had a cancer diagnosis at baseline; 408 self-reported either a cancer 
or an hospitalization for cancer but these cases were not confirmed owing to the following 
reasons: lack of written consent to participate in the diagnosis validation survey (N=296 
volunteers including 17 who died before the onset of the survey), death of the volunteer 
(N=7), refusal to respond to the survey when contacted (N=2) or failure to contact the 
volunteer and his or her physician (N=103); 124 died from a cancer without having reported a 
diagnosis of cancer or an hospitalization for cancer during the follow-up. These 124 
individuals were excluded from subsequent analyses to increase the specificity of cancer 
diagnoses, except in model 2b, which aimed at optimizing the diagnosis sensitivity (see 
above). The study population included 13,768 participants whose characteristics are displayed 
in Table 1. 
Associations between personality scores and discrete and continuous variables are 
displayed in Table 2 and 3, respectively. 
During a median follow-up of 16.0 years [range: 9 days-16 years], 1139 (8.3%) 
participants (881 men, 258 women) received at least one diagnosis of a primary cancer (other 
than nonmelanoma skin cancer), including 121 participants (103 men, 18 women) who self-
reported a cancer or a hospitalization for cancer during follow-up but died from a cancer 
before the diagnosis validation survey. Among participants who received at least one 
diagnosis of a primary cancer, the mean duration of follow-up prior to the first cancer 
diagnosis was 9.3 years. There were 413 prostate cancer cases among men, 146 breast cancer 
cases among women, 124 colorectal cancer cases (106 men, 18 women), 137 smoking-related 
cancer cases (132 men, 5 women), and 352 cases of other cancers (256 men, 96 women). 
Among this residual category, the most frequent cancers were lymphoid and hematopoietic 
cancers (N=95), cancers of the urinary organs (N=49), non colorectal digestive cancers 
(N=45) and melanomas (N=44). Associations between covariates and cancer incidence in 
multivariate analyses are displayed in Table 4. 
Associations between personality scores and cancer incidence are displayed in Table 5. 
Type 1 personality was not associated with an increased risk of cancer, regardless of cancer 
site, and was even associated with a decreased risk of breast cancer in women. Type 5 
personality score was associated with an increased risk of other cancers. Hostility was 
associated with an increased risk of smoking-related cancers in model 1, but no longer in 
model 2a (HR change: -56%). Indeed, this association was no longer significant when further 
adjusting model 1 with smoking only (HR for one standard deviation: 1.14, 95% CI: 0.96-
1.35, p=.13, HR change: -38%). Type A was not associated with the risk of cancer, regardless 
of cancer site. Including participants who died from a cancer without having reported a cancer 
during the follow-up (model 2b) or excluding those who reported a cancer during the follow-
up but died from a cancer before the diagnosis validation survey (model 2c) yielded similar 
results. There was no interaction between gender and Type 5 personality as regards its 
association with other cancers (Wald‟s statistic = 0.717, degree of freedom = 1, p=.40). 
Some post hoc analyses were also performed. 
To examine a potential dose-response relationship between Type 1 and the risk of breast 
cancer, and between Type 5 and the risk of other cancers, we divided these personality scores 
into quartiles. As regards Type 5 personality, we found that the highest quartile (versus the 
lowest) was significantly associated with an increased risk of other cancers, with intermediate 
HR for the second and third quartiles (Table 6). As regards Type 1 personality, we did not 
find evidence for a clear dose-response relationship, the lowest HR being associated with the 
third quartile, with intermediate HR for the second and the fourth quartiles (Table 6). 
To examine whether Type 1 and Type 5 were associated with biases in reporting 
diseases, we examined the correlations between the total number of diseases reported by each 
participant in the 1993 questionnaire and these personality scores. It was positively associated 
with Type 1 personality (r = 0.129, p<.001) and negatively associated with Type 5 personality 
(r = -0.055, p<.001), suggesting that Type 1 was not associated with under-reporting diseases 
and that Type 5 personality was not associated with over-reporting diseases. 
To examine the validity and the independence of Type 1 and Type 5 measures, we 
performed a principal component analysis over the 20 items of the two personality subscales. 
The Kaiser-Meyer-Olkin measure of sampling adequacy was 0.78 and the Bartlett's test of 
sphericity was significant (χ2=28124.742, df=190, p<.001). As expected, the scree test was 
clearly consistent with a two-factor solution. After varimax rotation, all except two items of 
the Type 1 subscale were selectively loading on the first factor and all except two items of the 
Type 5 subscale were selectively loading on the second factor. Computing the two personality 
scores without these items yielded slightly higher alpha coefficients for both Type 1 
(Cronbach‟s α = 0.63) and Type 5 (Cronbach‟s α = 0.58). Type 1 was still associated with a 
decreased risk of breast cancer (HR for one standard deviation: 0.83, 95% CI: 0.69-1.00, 
p=.047) and Type 5 was still associated with an increased risk of other cancers (HR for one 
standard deviation: 1.19, 95% CI: 1.06-1.34, p=.004). 
Discussion 
 
To our knowledge, this is the first large-scale prospective study to examine the 
association between the PSI personality types and the incidence of cancer. Adjusting for an 
extensive set of covariates, we found no evidence for an association between Type 1 
personality and an increased risk of cancer, regardless of cancer site. Type 1 personality was 
indeed associated with a decreased risk of breast cancer. This association remained significant 
in sensitivity analyses but there was no evidence for a clear dose-response relationship. Type 
5 personality, which is characterized by rational/anti-emotional tendencies, was associated 
with an increased risk of other cancers. Post hoc analyses with a quartile approach suggested a 
dose-response relationship. Type 5 personality, however, was not associated with the risk of 
breast, prostate, colorectal or smoking-related cancers. In addition, there was a positive 
association between hostility and the risk of smoking-related cancers, which was explained by 
smoking habits. Finally, Type A personality was not associated with the risk of cancer, 
regardless of cancer site.  
Strengths of the present study include its large sample size, the long duration of follow-
up (i.e. 15.2 years on average), the wide set of covariates, the study of different cancer sites 
and the study of cancer incidence rather than mortality. Cancer diagnoses were carefully 
ascertained and validated and sensitivity analyses yielded similar results. Our data are 
consistent with known associations for established risk factors such as age, alcohol 
consumption and smoking, as well as for social and demographic variables and protective 
factors (33). They are also consistent with the lack of association between rational/anti-
emotional tendencies and the incidence of breast cancer (19, 21). In comparison with previous 
studies that failed to find significant associations between other measures of rational/anti-
emotional tendencies and cancer incidence (18, 20), the present study had more statistical 
power owing to a five to ten-fold greater number of events. Indeed, one of these studies found 
a positive association between control of depressive feelings and cancer mortality, with a 
similar trend for cancer incidence (20). 
Several limitations should nevertheless be acknowledged. Although most of the cancer 
cases were thoroughly ascertained and validated, thus making false positives unlikely, there 
may have been false negatives for cancer cases that were diagnosed after retirement. Indeed, 
124 individuals died from a cancer without having self-reported a diagnosis of cancer or a 
hospitalization for cancer during the follow-up. Several of them died from a cancer with poor 
prognosis (e.g. lung cancer) and the lack of self-reported cancer incidence data may be due to 
the short time period between diagnosis and death. However, including these participants in 
the analysis yielded similar results. Owing to the possibility of false negatives, our results 
may partially result from reporting biases. For instance, the tendency to report cancer or to 
engage in screening procedures could have been lower in Type 1 and higher in Type 5. 
Theses hypotheses are, however, unlikely. First, the number of self-reported diseases tended 
to be positively associated with Type 1 and negatively with Type 5. Second, Type 1 and Type 
5 were not associated with an increased risk of prostate cancer diagnosis, which may capture 
both real incidence and excessive screening based on the prostate specific antigen, or with 
colorectal cancer, for which routine screening is recommended for everyone over 50 years in 
France (33). 
Since our study is observational, our findings should be interpreted with caution. For 
instance, our results might have been partially confounded by some unmeasured variables, 
such as genetic factors or early socioeconomic adversity, or mediated by unmeasured health 
behaviors, such as adherence to medical recommendations or preventive measures. For 
instance, the inverse association between Type 1 and the risk of breast cancer may have been 
partially explained by some specific risk factors such as exposure to estrogen, history of full-
term pregnancies or breastfeeding. As regards potential mediators, personality factors have 
been found to be associated with behavioral risk factors such as smoking status or alcohol 
consumption. In the present study, the association of hostility with the incidence of smoking-
related cancers vanished after adjustment for health behaviors, as did similar trends regarding 
Type 1 and Type 5. Such findings could be of some relevance for cancer prevention. For 
instance, smoking cessation programs may benefit from taking into account the potential role 
of smoking in coping with hostile thoughts and feelings. Given the considerable role of 
smoking as a risk factor, one may argue that residual confounding due to inadequate 
adjustment may account for previous findings linking personality with smoking-related 
cancers (10). It is thus noteworthy that smoking-related cancers were not included in the other 
sites category, which was significantly associated with Type 5 personality. Likewise, although 
Type 5 personality appeared to be connected with alcohol consumption, the risk of cancers at 
other sites was not. However, the measure of some health behaviors, such as diet or physical 
exercise, may have been too crude to rule out residual confounding. 
Our results may also have been confounded by shared biological processes. For 
instance, immune and inflammatory processes that are involved in cancer onset and 
progression may also influence psychological processes that are eventually captured by 
personality measures (34-36). Direct evidence linking personality with cancer risk through 
immune mechanisms is sparse in humans (37, 38). However, the activity of some brain 
regions involved in the neural underpinnings of personality, such as the medial prefrontal 
cortex (39), has been found to mediate the bi-directional relationships between immune and 
psychological processes among healthy subjects (40, 41). Immune processes may therefore 
shape both cancer vulnerability and some aspects of personality, potentially accounting for 
the present results without any causal link between personality and cancer. Since combined 
analyses across cancer sites may blur associations, site-specific analyses are needed. Further 
studies may look for a specific association between Type 5 personality and cancer sites for 
which immune mechanisms are central, such as those associated with viral infection (e.g. B-
cell lymphomas or cervical cancers) (34) or those in which immune therapy have proven 
efficacy (e.g. malignant melanomas, kidney cancers) (42). Interestingly, most of theses 
cancers were included into the “other sites” category, suggesting promising research avenues 
for future studies with a greater number of incident cases of these cancers. Our study was 
indeed underpowered to further test this hypothesis, as a result of the rather young age of 
study participants at the end of the follow-up. 
Other limitations should be considered. First, although the GAZEL cohort covers all 
regions of France, various areas ranging from small villages to large cities and a wide range 
of socioeconomic status and occupations, it is not representative of the general population as 
it includes only middle-aged working individuals with employment security and excluded 
certain categories of the population (e.g. agricultural workers, self-employed, foreigners) (13). 
Furthermore, cancer incidence among the employees of the French national gas and electricity 
company was found to be lower in those who participated in the GAZEL Cohort Study than in 
those who did not (43). Although we believe that this selection is unlikely to have 
systematically biased our results, we cannot formally rule out this hypothesis. Third, Type 1 
and Type 5 personality measures had low internal consistency and 3-month retest coefficients 
and Type A personality measure also had a low internal consistency. Poor measurement of 
these personality constructs might have contributed to the generally null pattern of results 
observed. Fourth, owing to the number of statistical tests performed, we cannot rule out a role 
of chance in our results. This might especially apply to the unexpected association between 
Type 1 and a reduced risk of breast cancer, as it did not demonstrate a clear dose-response 
relationship.  
Although there is strong evidence to dismiss the relationships between general 
personality constructs and cancer risk (8), several personality constructs have not been 
properly tested yet. To our knowledge, our study is the first that examined the association 
between cancer incidence and the personality types posited to be “cancer-prone” by 
Grossarth-Maticek and Eysenck (14). Although one might have expected negative results, 
especially given the serious concerns surrounding the early reports by these authors (15, 16), 
we found some support for a link between rational/anti-emotional tendencies and the risk of at 
least some cancers. Should these findings be replicated, further studies would be needed to 
explore the underlying mechanisms of this association, as potential prevention strategies 
should address the processes through which psychological processes may be associated with 
cancer, rather than these processes per se (44). 
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Table 1. Characteristics of the participants. 
 
 MEN (N=10,136 WOMEN (N=3,632) 
CONTINUOUS VARIABLES Mean (SD) Missing: N (%) Mean (SD) Missing: N (%) 
Age (years) 48.5 (2.9) 0 (0.0) 45.7 (4.2) 0 (0.0) 
Perceived health status 5.7 (1.3) 0 (0.0) 5.5 (1.3) 1 (0.0) 
CATEGORICAL VARIABLES N (%) Missing: N (%) N (%) Missing: N (%) 
Occupational grade  5 (0.0)  5 (0.1) 
Blue-collar workers, clerks 1092 (10.8)  787 (21.7)  
First-line supervisors, sales 
representatives 
5221 (51.5)  2452 (67.6)  
Management 3818 (37.7)  388 (10.7)  
Alcohol consumption  295 (2.9)  88 (2.4) 
Non-drinkers 818 (8.3)  806 (22.7)  
Occasional and moderate drinkers 7472 (75.9)  2596 (73.3)  
Heavy drinkers 1551 (15.8)  142 (4.0)  
Smoking  64 (0.6)  12 (0.3) 
Never-smokers 3729 (37.0)  2450 (67.7)  
Ex-smokers < 20 pack-years 2792 (27.7)  527 (14.6)  
Ex-smokers ≥ 20 pack-years 976 (9.7)  362 (10.0)  
Current smokers < 20 pack-years 1399 (13.9)  97 (2.7)  
Current smokers ≥ 20 pack-years 1176 (11.7)  184 (5.1)  
Fruits consumption  516 (5.1)  252 (6.9) 
< 1 × / week 733 (7.6)  197 (5.8)  
1-2 × / week 1367 (14.2)  316 (9.3)  
> 2 × / week 7520 (78.2)  2867 (84.8)  
Vegetables consumption  586 (5.8)  269 (7.4) 
< 1 × / week 242 (2.5)  56 (1.7)  
1-2 × / week 3400 (35.6)  949 (28.2)  
> 2 × / week 5908 (61.9)  2358 (70.1)  
BMI  38 (0.4)  25 (0.7) 
<18.5 30 (0.3)  139 (3.9)  
18.5-24.99 4451 (44.1)  2700 (74.9)  
25-29.99 4895 (48.5)  594 (16.5)  
≥30 722 (7.1)  174 (4.8)  
Physical activity  592 (5.8)  308 (8.5) 
≥ 1 × / week 3493 (36.6)  1129 (34.0)  
Occasionally 3234 (33.9)  884 (26.6)  
None 2817 (29.5)  1311 (39.4)  
BMI: Body Mass Index; SD: Standard Deviation.
Table 2. Associations between personality variables and discrete covariates. 
 Type 1 Type 5 Hostility Type A 
 Mean SD p Mean SD p Mean SD p Mean SD p 
Gender   <.001   <.001   <.001   <.001 
Male 3.7 2.1  6.3 1.9  28.2 10.0  52.8 7.7  
Female 4.0 2.2  5.6 2.1  29.5 9.7  54.4 7.5  
Occupational grade   <.001
a
   <.001
a
   <.001   <.001
a
 
Blue-collar workers, clerks 4.1 2.2  6.0 1.9  30.5 10.4  51.8 7.9  
First-line supervisors, sales representatives 3.8 2.1  6.1 2.0  29.1 10.0  52.9 7.7  
Management 3.5 2.1  6.2 2.1  26.7 9.3  54.4 7.3  
Alcohol consumption   .03   .004
a
   <.001   .005 
Non-drinkers 3.9 2.1  6.0 2.0  28.4 10.4  53.3 7.9  
Occasional and moderate drinkers 3.7 2.1  6.1 2.0  28.2 9.7  53.3 7.6  
Heavy drinkers 3.8 2.1  6.2 2.0  30.0 10.4  52.6 7.7  
Smoking   <.001   .24   <.001   .04 
Never-smokers 3.9 2.2  6.1 2.0  27.5 9.9  53.2 7.6  
Ex-smokers < 20 pack-years 3.6 2.0  6.1 2.0  28.7 9.7  53.3 7.4  
Ex-smokers ≥ 20 pack-years 3.7 2.0  6.1 2.0  29.0 9.8  53.3 7.8  
Current smokers < 20 pack-years 3.7 2.0  6.1 2.1  30.7 9.9  53.6 7.8  
Current smokers ≥ 20 pack-years 3.9 2.1  6.2 2.0  30.2 10.2  52.8 8.1  
Fruits consumption   .02
a
   .32   <.001
a
   .68 
< 1 × / week 4.0 2.1  6.1 2.0  29.8 10.2  53.4 8.1  
1-2 × / week 3.8 2.1  6.1 2.0  29.1 10.1  53.1 7.5  
> 2 × / week 3.7 2.1  6.1 2.0  28.2 9.8  53.2 7.6  
Vegetables consumption   .045   .16   <.001   .99 
< 1 × / week 4.1 2.2  6.2 2.1  31.2 10.4  53.3 8.5  
1-2 × / week 3.7 2.1  6.2 2.0  28.9 10.0  53.2 7.5  
> 2 × / week 3.8 2.1  6.1 2.0  28.2 9.8  53.2 7.7  
BMI   .001   <.001   <.001   .16 
<18.5 4.2 2.5  5.7 2.1  29.1 9.3  53.5 8.0  
18.5-24.99 3.8 2.1  6.1 2.0  28.1 9.9  53.3 7.6  
25-29.99 3.7 2.1  6.2 2.0  28.8 10.0  53.2 7.7  
≥30 3.9 2.1  6.1 2.0  30.0 10.1  52.7 8.0  
Physical activity   <.001   .08
a
   <.001
a
   .12 
≥ 1 × / week 3.6 2.1  6.1 2.0  28.0 9.8  53.0 7.5  
Occasionally 3.7 2.1  6.1 2.0  28.4 9.7  53.4 7.5  
None 4.0 2.2  6.2 2.0  29.0 10.3  53.2 8.0  
BMI: Body Mass Index; SD: Standard Deviation. 
ANOVAs were computed to examine the relation of personality scores with continuous and discrete covariates. 
a
 p<.05 for linearity and p≥.10 for deviation from linearity. 
Table 3. Pearson’s correlation coefficients between personality variables and continuous variables. 
 
 Type 1 Type 5 Hostility Type A Age 
Type 5 0.194***     
Hostility 0.091*** -0.006    
Type A -0.137*** -0.071*** 0.309***   
Age 0.027** 0.095*** -0.042*** -0.074***  
Perceived health status -0.145*** 0.017* -0.211*** -0.079*** 0.008 
* p<.05; ** p<.01; *** p<.001.
Table 4. Associations between cancer incidence and covariates in multivariate analyses (Hazard Ratios and 95% confidence interval). 
 
 Prostate (men) Breast (women) Colorectal Smoking-related Other sites 
 N = 368 / 8,877 N = 125 / 3,094 N = 114 / 11,973 N = 113 / 11,968 N = 301 / 11,973 
Age 1.11*** [1.07-1.15] 1.05* [1.00-1.09] 1.08** [1.02-1.15] 0.96 [0.90-1.03] 1.04* [1.00-1.07] 
Gender      
Male - - 1.00 1.00 1.00 
Female - - 0.62 [0.35-1.11] 0.11*** [0.04-0.32] 1.21 [0.89-1.65] 
Occupational grade      
Blue-collar workers, clerks 1.00 1.00 1.00 1.00 1.00 
First-line supervisors, sales representatives 1.56† [0.98-2.49] 0.97 [0.62-1.52] 1.14 [0.60-2.17] 0.59* [0.36-0.96] 0.99 [0.69-1.43] 
Management 2.17** [1.36-3.45] 1.20 [0.64-2.25] 1.17 [0.59-2.31] 0.40** [0.23-0.71] 1.35 [0.91-2.00] 
Alcohol consumption      
Non-drinkers 1.00 1.00 1.00 1.00 1.00 
Occasional and moderate drinkers 1.19 [0.78-1.80] 1.19 [0.75-1.89] 1.54 [0.74-3.19] 0.99 [0.52-1.88] 0.99 [0.69-1.42] 
Heavy drinkers 1.34 [0.83-2.16] 2.39* [1.11-5.16] 1.38 [0.57-3.33] 1.07 [0.52-2.18] 1.05 [0.65-1.68] 
Smoking      
Never-smokers 1.00 1.00 1.00 1.00 1.00 
Ex-smokers < 20 pack-years 1.19 [0.93-1.51] 0.97 [0.57-1.64] 0.86 [0.54-1.37] 1.79 [0.88-3.66] 0.84 [0.62-1.14] 
Ex-smokers ≥ 20 pack-years 0.99 [0.68-1.44] 1.09 [0.61-1.97] 0.70 [0.33-1.47] 2.31† [0.97-5.52] 1.14 [0.78-1.67] 
Current smokers < 20 pack-years 0.74 [0.52-1.06] 0.84 [0.26-2.67] 1.14 [0.65-2.00] 4.41*** [2.19-8.89] 1.00 [0.68-1.48] 
Current smokers ≥ 20 pack-years 0.60* [0.39-0.93] 0.74 [0.30-1.87] 0.65 [0.30-1.40] 12.33*** [6.70-22.67] 0.93 [0.61-1.42] 
Fruits consumption      
< 1 × / week 1.00 1.00 1.00 1.00 1.00 
1-2 × / week 1.18 [0.73-1.90] 0.98 [0.35-2.70] 1.14 [0.50-2.60] 0.44* [0.23-0.87] 1.13 [0.66-1.94] 
> 2 × / week 1.01 [0.66-1.54] 1.29 [0.56-2.97] 0.93 [0.45-1.91] 0.62† [0.38-1.03] 1.01 [0.63-1.62] 
Vegetables consumption      
< 1 × / week 1.00 1.00 1.00 1.00 1.00 
1-2 × / week 0.72 [0.39-1.30] 2.52 [0.35-18.44] 0.29** [0.13-0.64] 1.45 [0.45-4.70] 1.14 [0.50-2.62] 
> 2 × / week 0.69 [0.38-1.25] 2.05 [0.28-14.80] 0.32** [0.15-0.69] 1.22 [0.38-3.96] 1.15 [0.51-2.62] 
BMI      
<18.5 0.90 [0.12-6.43] 1.00 [0.37-2.75] 2.42 [0.58-10.15] 2.76 [0.64-11.78] 0.85 [0.27-2.70] 
18.5-24.99 1.00 1.00 1.00 1.00 1.00 
25-29.99 0.91 [0.74-1.13] 1.01 [0.63-1.60] 1.08 [0.73-1.60] 0.87 [0.59-1.28] 0.96 [0.75-1.23] 
≥30 1.01 [0.66-1.55] 0.32 [0.08-1.32] 0.52 [0.19-1.46] 0.26* [0.08-0.84] 1.00 [0.61-1.62] 
Physical activity      
≥ 1 × / week 0.76* [0.59-0.99] 0.92 [0.60-1.39] 0.89 [0.56-1.41] 0.58* [0.34-0.99] 1.09 [0.82-1.46] 
Occasionally 0.97 [0.76-1.25] 0.82 [0.52-1.29] 0.96 [0.60-1.52] 1.00 [0.66-1.52] 1.15 [0.86-1.53] 
None 1.00 1.00 1.00 1.00 1.00 
Perceived health status 1.02 [0.94-1.11] 0.98 [0.86-1.13] 1.07 [0.92-1.24] 0.94 [0.82-1.08] 0.89** [0.81-0.97] 
BMI: Body Mass Index; N: number of events / number of participants at risk. 
Hazard ratios and 95% confidence interval were computed through Cox regressions. 
† p<.10; * p<.05; ** p<.01; *** p<.001. 
 Table 5. Associations between cancer incidence and personality variables (Hazard ratio per standard deviation and 95% confidence interval). 
 
 All sites Prostate (men) Breast (women) Colorectal Smoking-related Other sites 
Unadjusted N = 1,139 / 13,767 N = 413 / 10,134 N = 146 / 3,631 N = 124 / 13,767 N = 137 / 13,759 N = 352 / 13,767 
Type 1 1.01 [0.96-1.07] 1.01 [0.92-1.12] 0.86 [0.74-1.01] 0.94 [0.78-1.12] 1.17 [0.99-1.37] 1.01 [0.91-1.12] 
Type 5 1.08** [1.02-1.15] 1.01 [0.92-1.12] 1.01 [0.86-1.18] 1.07 [0.90-1.28] 1.21* [1.02-1.44] 1.15** [1.04-1.28] 
Hostility 1.05 [0.99-1.11] 1.05 [0.96-1.16] 0.91 [0.77-1.08] 0.88 [0.74-1.06] 1.29** [1.09-1.52] 1.07 [0.97-1.19] 
Type A 1.00 [0.94-1.06] 1.03 [0.94-1.14] 1.01 [0.85-1.19] 0.91 [0.77-1.09] 0.85 [0.72-1.00] 1.09 [0.98-1.21] 
Model 1 N = 1,133 / 13,694 N = 412 / 10,091 N = 145 / 3,601 N = 124 / 13,694 N = 136 / 13,687 N = 348 / 13,694 
Type 1 1.00 [0.94-1.06] 1.03 [0.93-1.13] 0.84* [0.71-0.99] 0.95 [0.79-1.14] 1.15 [0.97-1.36] 0.98 [0.88-1.09] 
Type 5 1.06* [1.00-1.13] 1.00 [0.91-1.11] 0.98 [0.84-1.15] 1.02 [0.85-1.22] 1.13 [0.95-1.35] 1.16** [1.04-1.29] 
Hostility 1.06 [0.99-1.12] 1.09 [0.98-1.20] 0.92 [0.77-1.09] 0.91 [0.76-1.09] 1.23* [1.04-1.45] 1.06 [0.95-1.18] 
Type A 1.00 [0.95-1.07] 1.01 [0.92-1.12] 1.03 [0.87-1.21] 0.95 [0.79-1.13] 0.92 [0.78-1.09] 1.07 [0.96-1.20] 
Model 2a N = 995 / 11,973 N = 368 / 8,877 N = 125 / 3,094 N = 114 / 11,973 N = 113 / 11,968 N = 301 / 11,973 
Type 1 0.97 [0.91-1.04] 1.01 [0.91-1.12] 0.81* [0.68-0.97] 0.90 [0.74-1.09] 1.07 [0.88-1.29] 0.96 [0.86-1.08] 
Type 5 1.06 [0.99-1.13] 1.02 [0.92-1.13] 0.96 [0.81-1.14] 1.05 [0.87-1.26] 1.04 [0.86-1.26] 1.17** [1.04-1.31] 
Hostility 1.03 [0.96-1.10] 1.08 [0.97-1.20] 0.90 [0.75-1.09] 0.89 [0.73-1.08] 1.10 [0.91-1.33] 1.06 [0.94-1.19] 
Type A 1.01 [0.95-1.08] 1.02 [0.92-1.13] 1.07 [0.89-1.28] 0.92 [0.76-1.11] 0.95 [0.79-1.14] 1.08 [0.96-1.21] 
Model 2b N = 1,055 / 12,033 N = 369 / 8,923 N = 127 / 3,108 N = 118 / 12,033 N = 133 / 12,028 N = 334 / 12,033 
Type 1 0.96 [0.90-1.02] 1.01 [0.91-1.12] 0.80* [0.67-0.96] 0.90 [0.75-1.09] 0.99 [0.83-1.18] 0.95 [0.85-1.06] 
Type 5 1.05 [0.98-1.11] 1.02 [0.92-1.13] 0.96 [0.81-1.13] 1.07 [0.89-1.29] 1.01 [0.85-1.20] 1.12* [1.01-1.26] 
Hostility 1.04 [0.97-1.10] 1.08 [0.97-1.20] 0.89 [0.74-1.08] 0.90 [0.74-1.09] 1.11 [0.94-1.32] 1.08 [0.96-1.20] 
Type A 1.01 [0.95-1.08] 1.02 [0.92-1.14] 1.06 [0.88-1.27] 0.92 [0.76-1.11] 1.00 [0.85-1.18] 1.06 [0.95-1.19] 
Model 2c N = 887 / 11,865 N = 360 / 8,785 N = 122 / 3,078 N = 95 / 11,865 N = 79 / 11,860 N = 258 / 11,865 
Type 1 0.97 [0.91-1.04] 1.01 [0.91-1.12] 0.81* [0.67-0.97] 0.91 [0.74-1.12] 1.13 [0.90-1.41] 0.93 [0.82-1.05] 
Type 5 1.06 [0.99-1.13] 1.02 [0.91-1.13] 0.97 [0.81-1.15] 1.11 [0.90-1.37] 1.00 [0.80-1.25] 1.18* [1.04-1.33] 
Hostility 1.05 [0.98-1.12] 1.08 [0.97-1.21] 0.88 [0.73-1.07] 0.89 [0.72-1.10] 1.15 [0.92-1.44] 1.11 [0.98-1.26] 
Type A 1.01 [0.95-1.08] 1.02 [0.92-1.14] 1.05 [0.87-1.27] 0.91 [0.74-1.11] 0.96 [0.77-1.20] 1.08 [0.95-1.22] 
N: number of events / number of participants at risk. 
Hazard ratios and 95% confidence interval were computed through Cox regressions. 
* p<.05; ** p<.01. 
Model 1 was adjusted for age, gender, occupational grade, BMI and perceived health status. 
Model 2a = model 1 further adjusted for health behaviors (i.e. alcohol consumption, smoking, fruits and vegetables consumption and sport). 
Model 2b = model 2a including participants who died from a cancer without having reported a cancer during the follow-up. 
Model 2c = model 2a excluding participants who reported a cancer during the follow-up but died from a cancer before the diagnosis validation survey. 
 
Table 6. Associations between Type 1 quartiles and breast cancers and between Type 5 quartiles and 
other cancers (Hazard Ratios and 95% confidence interval). 
 
 Type 1 and breast cancers (women) Type 5 and other cancers 
 Model 1 Model 2a Model 1 Model 2a 
 N = 145 / 3,601 N = 125 / 3,094 N = 348 / 13,694 N = 301 / 11,973 
Quartile 2 vs. 1 0.68 [0.43-1.09] 0.63 [0.38-1.04] 1.20 [0.83-1.74] 1.22 [0.82-1.81] 
Quartile 3 vs. 1 0.48** [0.29-0.80] 0.42** [0.24-0.73] 1.28 [0.93-1.75] 1.25 [0.89-1.75] 
Quartile 4 vs. 1 0.64 [0.38-1.06] 0.56* [0.33-0.97] 1.53** [1.11-2.12] 1.51* [1.07-2.14] 
N: number of events / number of participants at risk. 
Hazard ratios and 95% confidence interval were computed through Cox regressions. 
* p<.05; ** p<.01. 
Model 1 was adjusted for age, gender, occupational grade, BMI and perceived health status. 
Model 2a = model 1 further adjusted for health behaviors (i.e. alcohol consumption, smoking, fruits and 
vegetables consumption and sport). 
 
